Clinical phenotype clustering in cardiovascular risk patients for the identification of responsive metabotypes after red wine polyphenol intake

Journal of Nutritional Biochemistry

Volumn 28, Issue , 2016, Pages 114-120

  Vázquez Fresno, Rosa ^a,b   Llorach, Rafael ^a   Perera, Alexandre ^c   Mandal, Rupasri ^b   Feliz, Miguel ^a   Tinahones, Francisco J ^d   Wishart, David S ^b   Andres Lacueva, Cristina ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITAT POLITÈCNICA DE CATALUNYA   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

Author keywords

4 Hydroxyphenylacetate; Cardiovascular disease; Gut microbiota; Metabolic phenotype; Metabolomics; Metabotype; NMR; Wine polyphenols

Indexed keywords

4 HYDROXYPHENYLACETIC ACID; BETAINE; DIMETHYLAMINE; FUCOSE; GALLIC ACID; GLUCOSE; LACTIC ACID; MANDELIC ACID; MANNITOL; METHANOL; POLYPHENOL; TARTARIC ACID; THREONINE;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BIOCHEMICAL ANALYSIS; CARDIOMETABOLIC RISK; CARDIOVASCULAR RISK; CLUSTER ANALYSIS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES MELLITUS; FEMALE; HUMAN; INTESTINE FLORA; MALE; METABOLISM; METABOLITE; METABOLOMICS; MIDDLE AGED; NORMAL HUMAN; OBESITY; PARTIAL LEAST SQUARES REGRESSION; PHENOTYPE; PROTON NUCLEAR MAGNETIC RESONANCE; RANDOMIZED CONTROLLED TRIAL; RED WINE; URINARY EXCRETION; CARDIOVASCULAR DISEASES; WINE;

CARDIOVASCULAR DISEASES; CLUSTER ANALYSIS; HUMANS; METABOLOMICS; PHENOTYPE; POLYPHENOLS; PROTON MAGNETIC RESONANCE SPECTROSCOPY; WINE;

EID: 84957810451     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2015.10.002     Document Type: Article

References (43)

1. Nicholson J.K., Holmes E., Kinross J.M., Darzi A.W., Takats Z., Lindon J.C. Metabolic phenotyping in clinical and surgical environments. Nature 2012, 491(7424):384-392.
2. Kinross J., Li J.V., Muirhead L.J., Nicholson J. Nutritional modulation of the metabonome: applications of metabolic phenotyping in translational nutritional research. Curr Opin Gastroenterol 2014, 30(2):196-207.
3. McNiven E.M.S., German J.B., Slupsky C.M. Analytical metabolomics: nutritional opportunities for personalized health. J Nutr Biochem 2011, 22(11):995-1002.
4. Cowan T.E., Palmnäs M.S.A., Yang J., Bomhof M.R., Ardell K.L., Reimer R.A., et al. Chronic coffee consumption in the diet-induced obese rat: impact on gut microbiota and serum metabolomics. J Nutr Biochem 2014, 25(4):489-495.
5. Brennan L. NMR-based metabolomics: from sample preparation to applications in nutrition research. Prog Nucl Magn Reson Spectrosc 2014, 83:42-49.
6. Rhee E.P., Gerszten R.E. Metabolomics and cardiovascular biomarker discovery. Clin Chem 2012, 58(1):139-147.
7. Dahlöf B. Cardiovascular disease risk factors: epidemiology and risk assessment. Am J Cardiol 2010, 105(1, Supplement):3A-9A.
8. Lewington S., Whitlock G., Clarke R., Sherliker P., Emberson J., Halsey J., et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007, 370(9602):1829-1839.
9. Kaptoge S., Di Angelantonio E., Lowe G., Pepys M.B., Thompson S.G., Collins R., et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010, 375(9709):132-140.
10. Wilson P.W., Meigs J.B., Sullivan L., Fox C.S., Nathan D.M., D'Agostino R.B. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med 2007, 167(10):1068-1074.
11. Wannamethee S.G., Papacosta O., Whincup P.H., Carson C., Thomas M.C., Lawlor D.A., et al. Assessing prediction of diabetes in older adults using different adiposity measures: a 7 year prospective study in 6,923 older men and women. Diabetologia 2010, 53(5):890-898.
12. Pradhan A.D., Manson J.E., Rifai N., Buring J.E., Ridker P.M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286(3):327-334.
13. Wang T.J., Larson M.G., Vasan R.S., Cheng S., Rhee E.P., McCabe E., et al. Metabolite profiles and the risk of developing diabetes. Nat Med 2011, 17(4):448-453.
14. Hu F.B. Metabolic profiling of diabetes: from black-box epidemiology to systems epidemiology. Clin Chem 2011, 57(9):1224-1226.
15. Dauchet L., Amouyel P., Dallongeville J. Fruits, vegetables and coronary heart disease. Nat Rev Cardiol 2009, 6(9):599-608.
16. Gresele P., Cerletti C., Guglielmini G., Pignatelli P., de Gaetano G., Violi F. Effects of resveratrol and other wine polyphenols on vascular function: an update. J Nutr Biochem 2011, 22(3):201-211.
17. Chiva-Blanch G., Urpi-Sarda M., Ros E., Arranz S., Valderas-Martínez P., Casas R., et al. Dealcoholized red wine decreases systolic and diastolic blood pressure and increases plasma nitric oxide: short communication. Circ Res 2012, 111(8):1065-1068.
18. Chiva-Blanch G., Urpi-Sarda M., Llorach R., Rotches-Ribalta M., Guillén M., Casas R., et al. Differential effects of polyphenols and alcohol of red wine on the expression of adhesion molecules and inflammatory cytokines related to atherosclerosis: a randomized clinical trial. Am J Clin Nutr 2012, 95(2):326-334.
19. Cardona F., Andrés-Lacueva C., Tulipani S., Tinahones F.J., Queipo-Ortuño M.I. Benefits of polyphenols on gut microbiota and implications in human health. J Nutr Biochem 2013, 24(8):1415-1422.
20. Estruch R., Martínez-González M.A., Corella D., Salas-Salvadó J., Ruiz-Gutiérrez V., Covas M.I., et al. Effects of a Mediterranean-style diet on cardiovascular risk factors: a randomized trial. Ann Intern Med 2006, 145(1):1-11.
21. 1H-NMR-based metabolomic analysis of the effect of moderate wine consumption on subjects with cardiovascular risk factors. Electrophoresis 2012, 33(15):2345-2354.
22. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Stat Methodol 1995, 57(1):289-300.
23. Apovian C.M., Gokce N. Obesity and cardiovascular disease. Circulation 2012, 125(9):1178-1182.
24. Collaboration HS Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002, 288(16):2015-2022.
25. Ndrepepa G., Kastrati A., Braun S., Koch W., Kölling K., Mehilli J., et al. Circulating homocysteine levels in patients with type 2 diabetes mellitus. Nutr Metab Cardiovasc Dis 2008, 18(1):66-73.
26. Horne B.D., Anderson J.L., John J.M., Weaver A., Bair T.L., Jensen K.R., et al. Which white blood cell subtypes predict increased cardiovascular risk?. J Am Coll Cardiol 2005, 45(10):1638-1643.
27. Yayan J. Erythrocyte sedimentation rate as a marker for coronary heart disease. Vasc Health Risk Manag 2012, 8219-8223.
28. Ahmed A., Zannad F., Love T.E., Tallaj J., Gheorghiade M., Ekundayo O.J., et al. A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure. Eur Heart J 2007, 28(11):1334-1343.
29. Menni C., Fauman E., Erte I., Perry J.R.B., Kastenmüller G., Shin S.-Y., et al. Biomarkers for type 2 diabetes and impaired fasting glucose using a nontargeted metabolomics approach. Diabetes 2013, 62(12):4270-4276.
30. Xie B., Waters M.J., Schirra H.J. Investigating potential mechanisms of obesity by metabolomics. J Biomed Biotechnol 2012, 2012. 10.1155/2012/805683.
31. Son H.S., Kim K.M., van den Berg F., Hwang G.S., Park W.M., Lee C.H., et al. 1H nuclear magnetic resonance-based metabolomic characterization of wines by grape varieties and production areas. J Agric Food Chem 2008, 56(17):8007-8016.
32. Vázquez-Fresno R., Llorach R., Urpi-Sarda M., Khymenets O., Bulló M., Corella D., et al. An NMR metabolomics approach reveals a combined-biomarkers model in a wine interventional trial with validation in free-living individuals of the PREDIMED study. Metabolomics 2014, 1-10.
33. Kim T.J., Silva J.L., Jung Y.S. Antibacterial activity of fresh and processed red muscadine juice and the role of their polar compounds on Escherichia coli O157:H7. J Appl Microbiol 2009, 107(2):533-539.
34. Regueiro J., Vallverdú-Queralt A., Simal-Gándara J., Estruch R., Lamuela-Raventós R. Development of a LC-ESI-MS/MS approach for the rapid quantification of main wine organic acids in human urine. J Agric Food Chem 2013, 61(27):6763-6768.
35. Urakami T., Kubota S., Nitadori Y., Harada K., Owada M., Kitagawa T. Annual incidence and clinical characteristics of type 2 diabetes in children as detected by urine glucose screening in the Tokyo metropolitan area. Diabetes Care 2005, 28(8):1876-1881.
36. Bouatra S., Aziat F., Mandal R., Guo A.C., Wilson M.R., Knox C., et al. The human urine metabolome. PLoS One 2013, 8(9):e73076. 10.1371/journal.pone.0073076.
37. Martin F.-P.J., Rezzi S., Peré-Trepat E., Kamlage B., Collino S., Leibold E., et al. Metabolic effects of dark chocolate consumption on energy, gut microbiota, and stress-related metabolism in free-living subjects. J Proteome Res 2009, 8(12):5568-5579.
38. Prior R.L., Rogers T.R., Khanal R.C., Wilkes S.E., Wu X., Howard L.R. Urinary excretion of phenolic acids in rats fed cranberry. J Agric Food Chem 2010, 58(7):3940-3949.
39. Moco S., Martin F.-P.J., Rezzi S. Metabolomics view on gut microbiome modulation by polyphenol-rich foods. J Proteome Res 2012, 11(10):4781-4790.
40. Nicholson J.K., Holmes E., Kinross J., Burcelin R., Gibson G., Jia W., et al. Host-gut microbiota metabolic interactions. Science 2012, 336(6086):1262-1267.
41. Shen J., Obin M.S., Zhao L. The gut microbiota, obesity and insulin resistance. Mol Aspects Med 2013, 34(1):39-58.
42. Tagliabue A., Elli M. The role of gut microbiota in human obesity: recent findings and future perspectives. Nutr Metab Cardiovasc Dis 2013, 23(3):160-168.
43. Everard A., Cani P.D. Diabetes, obesity and gut microbiota. Best Pract Res Clin Gastroenterol 2013, 27(1):73-83.